3 best performing ASX shares in the week of 11 April 2022
Marc Kennis, April 19, 2022
Best performing ASX shares
The three best performing ASX shares in the week of 11 April 2022 were CZR Resources (ASX:CZR), up 100%, 4DS Memory (ASX:4DS), up 38.2%, and Oncosil Medical (ASX:OSL), up 37.2%.
GET A 30-DAY FREE TRIAL TO STOCKS DOWN UNDER
1. CZR Resources (ASX:CZR)
Industry: Resources
CZR Resources (ASX:CZR, formerly Coziron Resources Limited) is a mining company exploring for iron-ore and manganese deposits. The company has exploration focussed on the Yarraloola, Shepherd Well, Croydon Top-Camp and Yarrie Projects in the Pilbara region and Buddadoo Project in the Yilgarn region of Western Australia.
Market Cap: $56m
12 month high / low: $0.0065 – $0.018

2. 4DS Memory (ASX:4DS)
Industry: Technology
4DS Memory Limited (ASX:4DS) is s a semiconductor development company of non-volatile memory technology which is involved in research and development of interface Switching ReRAM technology for next generation storage in mobile and cloud. 4DS has facilities located in Silicon Valley.
Market Cap: $150M
12 month high / low: $0.0455 – $0.245

3. Oncosil Medical (ASX:OSL)
Industry: Healthcare
Oncosil Medical (ASX:OSL) is an Australian based and ASX listed medical device company focused on localised treatments for patients with pancreatic and liver cancer. OncoSil’s lead product, OncoSil is a first in class medical device with targeted radioactive isotope (Phosphorous-32), implanted directly into a patient’s pancreatic tumors via an endoscopi ultrasound.
Market Cap: $47m
12 month high / low: $0.033 – $0.105

Learn more about ASX-listed stocks with
Stocks Down Under!
Subscribe to Stocks Down Under today!
No credit card needed and the trial expires automatically.
Blog Categories
Get the Latest Insider Trades on ASX!
Recent Posts
Boss Energy (ASX:BOE) Production Downgrade, Rain-Driven Disruption, and Why FY27 Is Now the Test
Honeymoon guidance cut to 1.40-1.45M lbs as weather and infrastructure delays compound Boss Energy Limited’s (ASX:BOE) Honeymoon uranium operation in…
Nufarm (ASX:NUF) 17% EBITDA Jump, A$50m Cost Cut, and the De-leveraging Story Investors Missed
Net debt falls A$130m while a strategy reset quietly changes the earnings picture Nufarm Limited’s (ASX:NUF) first-half update landed this…
Immutep (ASX:IMM) wins FDA orphan status as efti Phase 2 hits 51.5% endpoint
Rebound gains fuel as FDA orphan tag backs 38-patient efti data Immutep (ASX:IMM) has received FDA orphan drug designation for…